Please login to the form below

Not currently logged in
Email:
Password:

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which grew 33% to DKK 1.75bn in local

Latest news

More from news
Approximately 13 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics